Arteriovenous fistula thrombosis is associated with increased all-cause and cardiovascular mortality in haemodialysis patients from the AURORA trial.
arteriovenous fistula
arteriovenous graft
cardiovascular mortality
chronic haemodialysis
survival
vascular access complication
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
07
09
2018
accepted:
29
03
2019
entrez:
22
2
2020
pubmed:
23
2
2020
medline:
23
2
2020
Statut:
epublish
Résumé
The impact of arteriovenous fistula (AVF) or graft (AVG) thrombosis on mortality has been sparsely studied. This study investigated the association between AVF/AVG thrombosis and all-cause and cardiovascular mortality. The data from 2439 patients with AVF or AVG undergoing maintenance haemodialysis (HD) included in the A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events trial (AURORA) were analysed using a time-dependent Cox model. The incidence of vascular access (VA) thrombosis was a pre-specified secondary outcome. During follow-up, 278 AVF and 94 AVG thromboses were documented. VA was restored at 22 ± 64 days after thrombosis (27 patients had no restoration with subsequent permanent central catheter). In multivariable survival analysis adjusted for potential confounders, the occurrence of AVF/AVG thrombosis was associated with increased early and late all-cause mortality, with a more pronounced association with early all-cause mortality {hazard ratio [HR] < 90 days 2.70 [95% confidence interval (CI) 1.83-3.97], P < 0.001; HR > 90 days 1.47 [1.20-1.80], P < 0.001}. In addition, the occurrence of AVF thrombosis was significantly associated with higher all-cause mortality, whether VA was restored within 7 days [HR 1.34 (95% CI 1.02-1.75), P = 0.036] or later than 7 days [HR 1.81 (95% CI 1.29-2.53), P = 0.001]. AVF/AVG thrombosis should be considered as a major clinical event since it is strongly associated with increased mortality in patients on maintenance HD, especially in the first 90 days after the event and when access restoration occurs >7 days after thrombosis. Clinicians should pay particular attention to the timing of VA restoration and the management of these patients during this high-risk period. The potential benefit of targeting overall patient risk with more aggressive treatment after AVF/AVG restoration should be further explored.
Sections du résumé
BACKGROUND
BACKGROUND
The impact of arteriovenous fistula (AVF) or graft (AVG) thrombosis on mortality has been sparsely studied. This study investigated the association between AVF/AVG thrombosis and all-cause and cardiovascular mortality.
METHODS
METHODS
The data from 2439 patients with AVF or AVG undergoing maintenance haemodialysis (HD) included in the A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events trial (AURORA) were analysed using a time-dependent Cox model. The incidence of vascular access (VA) thrombosis was a pre-specified secondary outcome.
RESULTS
RESULTS
During follow-up, 278 AVF and 94 AVG thromboses were documented. VA was restored at 22 ± 64 days after thrombosis (27 patients had no restoration with subsequent permanent central catheter). In multivariable survival analysis adjusted for potential confounders, the occurrence of AVF/AVG thrombosis was associated with increased early and late all-cause mortality, with a more pronounced association with early all-cause mortality {hazard ratio [HR] < 90 days 2.70 [95% confidence interval (CI) 1.83-3.97], P < 0.001; HR > 90 days 1.47 [1.20-1.80], P < 0.001}. In addition, the occurrence of AVF thrombosis was significantly associated with higher all-cause mortality, whether VA was restored within 7 days [HR 1.34 (95% CI 1.02-1.75), P = 0.036] or later than 7 days [HR 1.81 (95% CI 1.29-2.53), P = 0.001].
CONCLUSIONS
CONCLUSIONS
AVF/AVG thrombosis should be considered as a major clinical event since it is strongly associated with increased mortality in patients on maintenance HD, especially in the first 90 days after the event and when access restoration occurs >7 days after thrombosis. Clinicians should pay particular attention to the timing of VA restoration and the management of these patients during this high-risk period. The potential benefit of targeting overall patient risk with more aggressive treatment after AVF/AVG restoration should be further explored.
Identifiants
pubmed: 32082562
doi: 10.1093/ckj/sfz048
pii: sfz048
pmc: PMC7025348
doi:
Types de publication
Journal Article
Langues
eng
Pagination
116-122Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA.
Références
Am J Kidney Dis. 2009 May;53(5):804-14
pubmed: 19268411
Nephrol Dial Transplant. 2013 May;28(5):1085-92
pubmed: 23543595
N Engl J Med. 2009 Apr 2;360(14):1395-407
pubmed: 19332456
Curr Control Trials Cardiovasc Med. 2005 May 23;6(1):9
pubmed: 15910680
Nephrol Dial Transplant. 2012 Aug;27(8):3043-8
pubmed: 22743335
J Am Soc Nephrol. 2004 Feb;15(2):477-86
pubmed: 14747396
Am J Nephrol. 2013;37(2):144-51
pubmed: 23392089
Am J Kidney Dis. 2006 Jul;48 Suppl 1:S176-247
pubmed: 16813989
Kidney Blood Press Res. 2007;30(5):314-22
pubmed: 17671394
Am J Kidney Dis. 2008 Apr;51(4):630-40
pubmed: 18371539
J Vasc Interv Radiol. 2003 Sep;14(9 Pt 2):S199-202
pubmed: 14514818
Nephrol Dial Transplant. 2008 Oct;23(10):3219-26
pubmed: 18511606
J Intern Med. 2012 May;271(5):463-71
pubmed: 21812843
J Am Soc Nephrol. 2017 Oct;28(10):3076-3088
pubmed: 28724774
J Cardiothorac Vasc Anesth. 2014 Apr;28(2):358-68
pubmed: 24008166
J Am Soc Nephrol. 2006 Mar;17(3 Suppl 1):S1-27
pubmed: 16497879
Hypertension. 2001 Sep;38(3):434-8
pubmed: 11566918
Nephrol Dial Transplant. 2014 Jan;29(1):29-40
pubmed: 24132242
Hypertension. 2001 Oct;38(4):938-42
pubmed: 11641313
J Am Soc Nephrol. 2006 Apr;17(4):1112-27
pubmed: 16565259
J Vasc Surg. 2008 Nov;48(5 Suppl):2S-25S
pubmed: 19000589
Semin Dial. 2018 May;31(3):244-257
pubmed: 29178510
Kidney Int. 2004 Oct;66(4):1622-32
pubmed: 15458459
Am J Kidney Dis. 2006 Mar;47(3):469-77
pubmed: 16490626